Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
TTNP > SEC Filings for TTNP > Form 8-K on 3-Jan-2013All Recent SEC Filings

Show all filings for TITAN PHARMACEUTICALS INC

Form 8-K for TITAN PHARMACEUTICALS INC


3-Jan-2013

Other Events, Financial Statements and Exhibits


Item 8.01. Other Events.

Titan Pharmaceuticals, Inc. has received notification from the U.S. Food and Drug Administration (FDA) that the New Drug Application (NDA) for ProbuphineŽ has been accepted for review and granted Priority Review designation by the FDA. Based upon the Prescription Drug User Fee Act, the FDA has set a target date of April 30, 2013 for FDA action on the NDA.

The press release dated January 2, 2013 announcing the Priority Review designation is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.



Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release dated January 2, 2013


  Add TTNP to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for TTNP - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.